ArticleTheranostics2021
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 16 citations in OpenAlex.
- A panel sequencing dataset of peripheral blood gene variations in pan-cancer.Scientific data · 2024Article
- Review
- Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.Experimental hematology & oncology · 2023Article
- Clinical characterization and genomic landscape of gynecological cancers among patients attending a Chinese hospital.Frontiers in oncology · 2023Article
- DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 20 institutions in 1 country.
Tao JiangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Liyan JiangDepartment of Respiration, Shanghai Chest Hospital, Shanghai, China.
Xiaorong DongCancer Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Kangsheng GuDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yueyin PanDepartment of Chemotherapy, Anhui Provincial Hospital, Hefei, Anhui, China.
Qin ShiDepartment of Oncology, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, Fujian, China.
Guojun ZhangDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Huijuan WangDepartment of Respiration, Henan Cancer Hospital, Zhengzhou, Henan, China.
Xiaochun ZhangMedical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Nong YangDepartment of Medical Oncology, Hunan Cancer Hospital, Changsha, China.
Yuping LiDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China.
Jianping XiongDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Tienan YiDepartment of Oncology, Xiang Yang Central Hospital, Xiangyang, Hubei, China.
Min PengDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Yong SongDepartment of Respiration, General Hospital of Eastern Theater Command of Chinese People's Liberation Army, Nanjing, Jiangsu, China.
Yun FanDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Jiuwei CuiCancer Center, The First Bethune Hospital of Jilin University, Changchun, Jilin, China.
Gongyan ChenDepartment of Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Wei TanDepartment of Respiratory Medicine, Weifang People's Hospital, Weifang, Shandong, China.
Aimin ZangMedical Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Qisen GuoDepartment of Internal Medicine, Shandong Cancer Hospital & Institute, Jinan, Shandong, China.
Guangqiang ZhaoDepartment of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Ziping WangMedical Oncology, Beijing Cancer Hospital, Beijing, China.
Jianxing HeDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Wenxiu YaoDepartment of Chemotherapy, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, China.
Xiaohong WuDepartment of Oncology, The Fourth People's Hospital of Wuxi, Wuxi, Jiangsu, China.
Kai ChenMedical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Xiaohua HuDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Chunhong HuDepartment of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lu YueDepartment of Oncology, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Da JiangMedical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Guangfa WangDepartment of Respiration, Peking University First Hospital, Beijing, China.
Junfeng LiuDepartment of Thoracic Surgery, 4th Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Guohua YuDepartment of Oncology, Weifang People's Hospital, Weifang, Shandong, China.
Junling LiMedical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
Henghui ZhangBeijing Genecast Biotechnology Co., Beijing, China.
Lihong WuBeijing Genecast Biotechnology Co., Beijing, China.
Lu FangBeijing Genecast Biotechnology Co., Beijing, China.
Dandan LiangBeijing Genecast Biotechnology Co., Beijing, China.
Yi ZhaoBeijing Genecast Biotechnology Co., Beijing, China.
Weihong ZhaoNanjing Luye Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
Wenmin XieNanjing Luye Pharmaceutical Co. Ltd, Nanjing, Jiangsu, China.
Shengxiang RenDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Caicun ZhouDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Genecast (China) · CNTongji University · CNWeifang People's Hospital · CNAnhui Provincial Hospital · CNCentral South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Anhui Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNFuzhou Pulmonary Hospital of Fujian · CNGuangxi Medical University · CNHarbin Medical University · CNHunan Cancer Hospital · CNKunming Medical University · CNNanchang University · CNPeking University · CNQingdao University · CNShanghai Chest Hospital · CNUnion Hospital · CNWuhan University · CNZhejiang Cancer Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Machine LearningAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCell-Free Nucleic AcidsCirculating Tumor DNACisplatinDeoxycytidineDNA Copy Number VariationsFemaleGemcitabineHumansLung NeoplasmsMaleMiddle AgedPaclitaxelCell-Free Nucleic AcidsCirculating Tumor DNACisplatinDeoxycytidineGemcitabinePaclitaxelcell-free DNAchemotherapymachine learningNon-small-cell lung cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.